source
- Novartis' DM1 drug del-desiran misses primary endpoint in Phase 3 HARBOR trialNovartis announced that its experimental therapy del-desiran did not improve muscle function in a pivotal Phase 3 study for myotonic dystrophy type 1 (DM1). The trial, called HARBOR, evaluated the…
- Novartis shares tumble after late-stage failure of Avidity-acquired drugNovartis announced that its late-stage trial of a drug it acquired from Avidity did not meet its primary endpoints. The setback follows a recent disappointment in a heart disease study, adding pres…